树突状细胞修复：在卵巢癌中释放治疗性免疫的新策略。
Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
作者信息
Chae Chang-Suk, Teran-Cabanillas Eli, Cubillos-Ruiz Juan R
机构信息
Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY, USA.
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
出版信息
Cancer Immunol Immunother. 2017 Aug;66(8):969-977. doi: 10.1007/s00262-017-1958-2. Epub 2017 Feb 18.
Abstract
Immune-based therapies that induce remarkable and durable responses against melanoma and lung cancer have unfortunately demonstrated limited success in ovarian cancer patients. This is likely due to the exceptional immunoregulatory nature of ovarian tumors, which employ numerous strategies to effectively suppress anti-tumor immunity. Here, we summarize a decade of research indicating that ovarian cancers possess an exquisite capacity to subvert the activity of host dendritic cells (DCs) as a key mechanism to impede the development and maintenance of protective T cell-based immune responses. Identifying, understanding, and disabling the precise mechanisms promoting DC dysfunction in ovarian cancer are, therefore, fundamental requirements for devising the next generation of successful immunotherapies against this devastating malignancy.
摘要
不幸的是，在黑色素瘤和肺癌患者中能诱导显著且持久反应的免疫疗法，在卵巢癌患者身上的成功率却有限。这可能是由于卵巢肿瘤具有特殊的免疫调节特性，它采用多种策略有效地抑制抗肿瘤免疫。在此，我们总结了十年的研究，表明卵巢癌具有精巧的能力来颠覆宿主树突状细胞（DCs）的活性，这是阻碍基于T细胞的保护性免疫反应发展和维持的关键机制。因此，识别、理解并消除促进卵巢癌中DC功能障碍的精确机制，是设计针对这种毁灭性恶性肿瘤的下一代成功免疫疗法的基本要求。
相似文献
1
Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.树突状细胞修复：在卵巢癌中释放治疗性免疫的新策略。
Cancer Immunol Immunother. 2017 Aug;66(8):969-977. doi: 10.1007/s00262-017-1958-2. Epub 2017 Feb 18.
2
Dendritic Cell Vaccines in Ovarian Cancer.树突状细胞瘤苗在卵巢癌中的应用。
Front Immunol. 2021 Jan 25;11:613773. doi: 10.3389/fimmu.2020.613773. eCollection 2020.
3
Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.5-氟尿嘧啶消除髓源性抑制细胞可增强基于树突状细胞的疫苗功能并改善肿瘤小鼠的免疫力。
Iran J Allergy Asthma Immunol. 2018 Feb;17(1):47-55.
4
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.一种基于佐剂/增强的疫苗平台能够有效地鉴定出 CD27 激动剂和耗竭髓源性抑制细胞，这两种疗法可以与卵巢癌中的检查点阻断疗法进行合理联合。
Cancer Immunol Immunother. 2021 Dec;70(12):3451-3460. doi: 10.1007/s00262-021-02936-1. Epub 2021 Apr 20.
5
Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune Responses .负载热休克条件化卵巢上皮癌细胞裂解物的树突状细胞可诱导 T 细胞依赖的抗肿瘤免疫应答。
J Immunol Res. 2019 Nov 25;2019:9631515. doi: 10.1155/2019/9631515. eCollection 2019.
6
Understanding dendritic cell immunotherapy in ovarian cancer.了解卵巢癌中的树突状细胞免疫疗法。
Expert Rev Anticancer Ther. 2016 Jun;16(6):643-52. doi: 10.1080/14737140.2016.1178576. Epub 2016 May 13.
7
Notch Signaling in Myeloid Cells as a Regulator of Tumor Immune Responses.髓系细胞中的Notch信号传导作为肿瘤免疫反应的调节因子
Front Immunol. 2018 Jun 4;9:1288. doi: 10.3389/fimmu.2018.01288. eCollection 2018.
8
A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.用自体次氯酸氧化卵巢癌细胞裂解物冲击的树突状细胞疫苗可诱导有效的广谱抗肿瘤免疫：从基础到临床。
Clin Cancer Res. 2013 Sep 1;19(17):4801-15. doi: 10.1158/1078-0432.CCR-13-1185. Epub 2013 Jul 9.
9
Understanding the cross-talk between ovarian tumors and immune cells: mechanisms for effective immunotherapies.了解卵巢肿瘤与免疫细胞之间的串扰：有效免疫疗法的机制。
Int Rev Immunol. 2011 Apr-Jun;30(2-3):71-86. doi: 10.3109/08830185.2011.561507.
10
Restoring immunosurveillance by dendritic cell vaccines and manipulation of the tumor microenvironment.通过树突状细胞疫苗恢复免疫监视并调控肿瘤微环境。
Immunobiology. 2015 Feb;220(2):243-8. doi: 10.1016/j.imbio.2014.11.007. Epub 2014 Nov 15.
引用本文的文献
1
IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer.胰岛素样生长因子1受体（IGF1R）抑制与程序性死亡受体1（PD-1）阻断可改善上皮性卵巢癌的抗肿瘤免疫反应。
Front Oncol. 2024 Oct 10;14:1410447. doi: 10.3389/fonc.2024.1410447. eCollection 2024.
2
Innate immune cells: Key players of orchestra in modulating tumor microenvironment (TME).固有免疫细胞：调节肿瘤微环境（TME）的管弦乐队中的关键角色。
Heliyon. 2024 Mar 3;10(5):e27480. doi: 10.1016/j.heliyon.2024.e27480. eCollection 2024 Mar 15.
3
Unlocking Dendritic Cell-Based Vaccine Efficacy through Genetic Modulation-How Soon Is Now?通过基因调控解锁树突状细胞疫苗的疗效——何时能实现？
Genes (Basel). 2023 Nov 23;14(12):2118. doi: 10.3390/genes14122118.
4
Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis.PD-1/PD-L1抑制剂治疗复发性和难治性卵巢癌的疗效与安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2023 Mar 13;14:1111061. doi: 10.3389/fphar.2023.1111061. eCollection 2023.
5
Tumor-Derived Lysophosphatidic Acid Blunts Protective Type I Interferon Responses in Ovarian Cancer.肿瘤衍生的溶血磷脂酸削弱卵巢癌中的保护性 I 型干扰素反应。
Cancer Discov. 2022 Aug 5;12(8):1904-1921. doi: 10.1158/2159-8290.CD-21-1181.
6
Cancer Stem Cells in Ovarian Cancer-A Source of Tumor Success and a Challenging Target for Novel Therapies.卵巢癌中的癌症干细胞——肿瘤成功的根源和新型治疗的挑战性靶点。
Int J Mol Sci. 2022 Feb 24;23(5):2496. doi: 10.3390/ijms23052496.
7
Natural Killer Cells: the Missing Link in Effective Treatment for High-Grade Serous Ovarian Carcinoma.自然杀伤细胞：高级别浆液性卵巢癌有效治疗的缺失环节。
Curr Treat Options Oncol. 2022 Feb;23(2):210-226. doi: 10.1007/s11864-021-00929-x. Epub 2022 Feb 22.
8
The Cancer Stem Cell Niche in Ovarian Cancer and Its Impact on Immune Surveillance.卵巢癌中的癌症干细胞生态位及其对免疫监视的影响。
Int J Mol Sci. 2021 Apr 15;22(8):4091. doi: 10.3390/ijms22084091.
9
IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer.卵巢癌肿瘤微环境中的 IL-10 信号传导。
Adv Exp Med Biol. 2021;1290:51-65. doi: 10.1007/978-3-030-55617-4_3.
10
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy.上皮性卵巢癌与免疫系统：生物学、相互作用、挑战及免疫治疗的潜在进展
J Clin Med. 2020 Sep 14;9(9):2967. doi: 10.3390/jcm9092967.
本文引用的文献
1
Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.凝集素型氧化型低密度脂蛋白受体-1可区分癌症患者中人类多形核髓源性抑制细胞群体。
Sci Immunol. 2016 Aug;1(2). doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.
2
The roles of microRNAs related with progression and metastasis in human cancers.与人类癌症进展和转移相关的微小RNA的作用。
Tumour Biol. 2016 Dec;37:15383–15397. doi: 10.1007/s13277-016-5436-9. Epub 2016 Oct 6.
3
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.T细胞癌症治疗需要CD40-CD40L激活肿瘤坏死因子以及诱导产生一氧化氮合酶的树突状细胞。
Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004.
4
Ovarian cancer.卵巢癌。
Nat Rev Dis Primers. 2016 Aug 25;2:16061. doi: 10.1038/nrdp.2016.61.
5
Management of relapsed ovarian cancer: a review.复发性卵巢癌的管理：综述
Springerplus. 2016 Jul 28;5(1):1197. doi: 10.1186/s40064-016-2660-0. eCollection 2016.
6
State-of-the-art of regulatory dendritic cells in cancer.癌症中调节性树突状细胞的研究现状。
Pharmacol Ther. 2016 Aug;164:97-104. doi: 10.1016/j.pharmthera.2016.04.003. Epub 2016 Apr 23.
7
Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells.Satb1 过表达驱动癌相关树突状细胞的肿瘤促进活性。
Cell Rep. 2016 Feb 23;14(7):1774-1786. doi: 10.1016/j.celrep.2016.01.056. Epub 2016 Feb 11.
8
Cancer statistics, 2016.癌症统计数据，2016 年。
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30. doi: 10.3322/caac.21332. Epub 2016 Jan 7.
9
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.抗 PD-1 抗体纳武利尤单抗治疗铂耐药卵巢癌患者的安全性和抗肿瘤活性。
J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8.
10
ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis.内质网应激传感器XBP1通过破坏树突状细胞稳态来控制抗肿瘤免疫。
Cell. 2015 Jun 18;161(7):1527-38. doi: 10.1016/j.cell.2015.05.025. Epub 2015 Jun 11.
Zotero 插件